Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Medel Sakartvelo | Pharma | 34.0% | 82nd pct | 110 |
| Jihelsi | Pharma | 32.5% | 78th pct | 110 |
| Tbilisi Medic | Pharma | 5.6% | 24th pct | 110 |
| New Pharma | Pharma | -0.2% | 15th pct | 110 |
| Neoparmi + | Pharma | -4.6% | 9th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Line item | Medel Sakartvelo | Neoparmi + | Jihelsi | Tbilisi Medic | New Pharma |
|---|---|---|---|---|---|
| Total Current Assets | 2,151 | 4,832 | 5,199 | 9,941 | 9,159 |
| Total Non-Current Assets | 0 | 855 | 133 | 8,743 | 502 |
| TOTAL ASSETS | 2,151 | 5,687 | 5,332 | 18,684 | 9,662 |
| Total Current Liabilities | 1,354 | 5,673 | 1,911 | 3,412 | 3,143 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 1,079 | 3,069 |
| TOTAL LIABILITIES | 1,354 | 5,673 | 1,911 | 4,491 | 6,212 |
| Total Equity | 797 | 14 | 3,420 | 14,193 | 3,450 |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 |
| Total Debt | 0 | 0 | 0 | 3,515 | 3,069 |
| Cash & Equivalents | 540 | 261 | 1,557 | 440 | 2 |
| Net Debt | -540 | -261 | -1,557 | 3,075 | 3,067 |